Conexiant

Outlet metrics

Domain Authority

Ranking

Global

#1114972

United States

#272846

Articles

First Targeted Therapy Approved for BP

2 days ago | conexiant.com | Kathryn Wighton

Dupilumab is now the first and only FDA-approved targeted therapy for bullous pemphigoid, demonstrating sustained disease remission and reduced corticosteroid dependence in a pivotal trial. The U.S. Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for adults with bullous pemphigoid (BP), a rare, chronic autoimmune skin disease characterized by pruritus, blistering, and widespread skin involvement.
FDA Approves At-Home Lupus Nephritis Therapy

4 days ago | conexiant.com | Kathryn Wighton

For the first time, children as young as 5 with active lupus nephritis can now receive belimumab treatment at home via a newly approved subcutaneous autoinjector. The U.S. Food and Drug Administration has approved a 200 mg/mL subcutaneous autoinjector formulation of belimumab (Benlysta) in pediatric patients aged 5 years and older with active lupus nephritis (LN) who are receiving standard therapy.
New Tool Estimates Amyloid Risk in Early Alzheimer’s

1 week ago | conexiant.com | Kathryn Wighton

A brief computerized test combined with a newly developed scoring system may help stratify older adults by risk of early Alzheimer's disease pathology and potentially reduce reliance on positron emission tomography imaging.
RSV Vaccine Approved for Younger Adults

2 weeks ago | conexiant.com | Kathryn Wighton

mRESVIA is now approved in the U.S. for adults aged 18 to 59 with chronic health conditions. The approval expands its prior indication that was limited to adults aged 60 years and older. Adults aged 18 to 59 years with chronic conditions—including cardiovascular and pulmonary diseases—are increasingly recognized as a high-risk population for respiratory syncytial virus (RSV)-related complications, including respiratory tract disease.
8-Week Oral Therapy Approved for Acute HCV

2 weeks ago | conexiant.com | Kathryn Wighton

Mavyret achieved a 96% cure rate in patients with acute hepatitis C following an 8-week oral treatment regimen. The FDA has expanded the indication for glecaprevir/pibrentasvir (Mavyret) in its approval as the first and only oral, 8-week, pangenotypic regimen for both acute and chronic hepatitis C virus (HCV) infection in patients aged 3 years and older without cirrhosis or with compensated cirrhosis.
New Fixed-Dose RSV Antibody Approved

2 weeks ago | conexiant.com | Kathryn Wighton

Enflonsia is the first RSV preventive approved for infants that uses a single fixed dose regardless of weight and offers protection throughout a full respiratory syncytial virus season. The FDA has approved enflonsia (clesrovimab-cfor), a long-acting monoclonal antibody developed by Merck, for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are entering their first RSV season.
FDA Monthly Round-up: Key May Updates

3 weeks ago | conexiant.com | Kathryn Wighton

From the first at-home human papillomavirus test and a biosimilar approved for broad immunologic indications, to new options in mitral valve replacement, chronic obstructive pulmonary disease care, and Alzheimer’s diagnostics, May’s U.S. Food and Drug Administration decisions spanned cardiology, pulmonology, neurology, and more. Here’s a comprehensive overview of the month’s most key decisions.
Conservative Mental Health Study Faces Retraction

3 weeks ago | conexiant.com | Kerri Miller |s’ Response

A study examining the association between political conservatism and mental health has been retracted by the Scandinavian Journal of Psychology following a postpublication peer review that identified “major errors involving methods, theory, and normatively biased language.”The article, Do Conservatives Really Have an Advantage in Mental Health? An Examination of Measurement Invariance, authored by Edward Dutton and Emil Kirkegaard, analyzed data from 2 Finnish survey samples (N = 848 and 4,978).
Big Tobacco's Medical Research Infiltrates Journals

3 weeks ago | conexiant.com | Kerri Miller

An investigation by The Investigative Desk and The BMJ has revealed that research funded by the tobacco industry continues to appear in highly cited medical journals, despite efforts by some publications to sever ties with the industry entirely. The findings document hundreds of relationships between major tobacco companies’ pharmaceutical subsidiaries and published medical research.
Does Sleep Duration Shape Oral Microbiomes?

3 weeks ago | conexiant.com | Kerri Miller

In a cross-sectional study of 1,332 U.S. adolescents and young adults, investigators found that individuals with long sleep durations exhibited significantly higher oral microbiome diversity compared with those with healthy sleep durations, according to research scheduled for presentation at SLEEP 2025. The study analyzed data from the 2011–2012 National Health and Nutrition Examination Survey (NHANES) for participants aged 16 to 26 years (mean age, 20.9 years; 50.4% female).